YCCI Society of Mentors

Scholars in YCCI’s educational programs are mentored and monitored by one or more senior faculty members from their department. In addition to these primary mentors, each Scholar is guided by a Career Development Committee. These mentors are senior faculty members from various departments who provide an unbiased perspective on Scholars’ progress and career development and make suggestions about future directions for both research and grant proposals. This integrated program led by an interdisciplinary team of mentors provides scholars with a significantly broader grounding in the essential elements of clinical and translational research. Scholars meet with their committee at least twice a year and committee members also attend Research in Progress meetings at which Scholars present their research.

Members of each committee are chosen based on the breadth, depth, and quality of their clinical and translational research, on their track records in mentoring young scientists, and on their shared commitment to developing an exciting intellectual environment for YCCI trainees. We are fortunate in having a very large pool of senior faculty members who are outstanding investigators in all types of clinical and translational science and who also are experienced mentors. Faculty members shown below are available to serve in the role of Career Development Mentors for our YCCI Scholars.

  • Robert Sherwin

    C.N.H. Long Professor Emeritus of Internal Medicine (Endocrinology)

    YCCI Director

    While most people move from the bench to the bedside during the course of their research careers, Robert Sherwin, MD, did just the opposite.

    In 1979, he and William Tamborlane, MD, devised a method of delivering insulin to children with Type 1 diabetes that more closely resembled how the pancreas produces it. Their study resulted in the development of the insulin pump, which is now used by hundreds of thousands of patients. This clinical research project also paved the way for the NIH-funded Diabetes Control and Complications Trial (DCCT), a landmark study which showed that treatment slows the onset and progression of diabetes-related complications.

    A concern about the long term consequences of repeated episodes of hypoglycemia led him to the lab, where he worked with rodents to better understand the brain’s response to low levels of glucose. His research began to shed light on how the hypothalamus activated the counterregulatory response in hypoglycemic animals. In the lab, Dr. Sherwin also helped to develop a mouse model of Type 1 diabetes that shares features of the human immune system to study how the disease triggers the autoimmune response.

    During the last decade, Dr. Sherwin has used cutting-edge imaging advances to move back to human studies to explore how to protect the brain better from hypoglycemia in Type 1 diabetes patients and also to understand feeding behavior in Type 2 diabetes and obesity. Working with a diverse group of researchers—from psychiatrists to pediatricians—his research has revealed dramatic differences between the brain responses of lean and obese children.

    As a seasoned researcher with over 35 years of continuous NIH support, Dr. Sherwin is uniquely qualified to serve as director of YCCI and PI of the CTSA. Because his work spans both clinical and basic science, he is well aware of the need to provide an infrastructure that affords the flexibility to support researchers whether their studies take place in the lab, the clinic, or the community. His commitment to ensuring that YCCI provides support services that span the entire life of research studies is fueled by a conviction that successful research requires a collaborative team effort.

    Having mentored over 100 young investigators, many of whom have gone on to become leaders in their fields, Dr. Sherwin is especially passionate about investing in the careers of tomorrow’s researchers. “I feel that we can have a real impact by directly providing mentorship and an environment where people can transition from being a clinician to being a clinician researcher,” he said.

    The enthusiasm with which Dr. Sherwin pursues his own work serves as an inspiration to his younger colleagues. “There are enough questions to answer,” he said. “For me, the most important thing is to get excited about what you’re doing.”

  • Marcella Nunez-Smith

    Associate Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Director, Equity Research and Innovation Center; Director, Center for Research Engagement; Core Faculty, National Clinician Scholars Program; Deputy Director of Health Equity Research and Workforce Development, Yale Center for Clinical Investigation; Director, Yale-Commonwealth Fund Fellowship

    Deputy Director of Health Equity Research and Workforce Development

    Growing up in St. Thomas, U.S. Virgin Islands, a health professional shortage area, Marcella Nunez-Smith, MD, MHS, remembers countless stories of loved ones and members of her community who struggled with their health or died prematurely. That experience led her to pursue a career in medicine and conduct research that focuses on vulnerable populations and their interactions with healthcare systems.

    Ever since her arrival at Yale as a fellow in the Robert Wood Johnson Foundation Clinical Scholars Program (CSP), Dr. Nunez-Smith has been on a mission to develop ways of addressing health and healthcare inequities wherever they are found: in patient settings, in the healthcare workforce, and in medical education. As a 2006 YCCI Scholar, she gathered preliminary data for what is now known as PreDict (Patient-Reported Experiences of Discrimination in Care Tool). PreDict is a tool that assesses the patient care experience and measures hospital performance with the goal of improving the quality of care delivery. “The Scholar award was tremendously helpful because it allowed me to launch a line of inquiry that was new and then provided me with the resources to complete the preliminary work that allowed us to be competitive for major NIH grants,” she said.

    Dr. Nunez-Smith went on to develop the Eastern Caribbean Health Outcomes Research Network (ECHORN), a collaborative multi-million dollar research study funded by the National Institute for Minority Health Disparities (NIMHD). ECHORN examines the risk factors and prevalence of cancer, diabetes, and heart disease in the Eastern Caribbean, a region for which such data are lacking.

    Both ECHORN and PreDict – which has spurred several related projects undertaken by her mentees – are now incorporated into the Equity Research and Innovation Center (ERIC), for which Dr. Nunez-Smith serves as director. ERIC builds on the local, national, and global experience of Dr. Nunez-Smith and 60 team members that are involved in research aimed at narrowing health and healthcare inequities, as well as disparities in the healthcare workforce and medical education.

    As a former YCCI Scholar, Dr. Nunez-Smith appreciates the benefits of mentorship and serves as academic advisor to Yale School of Medicine students. She also continues her involvement with the CSP as a core faculty member of the Scholars Program and co-director of Community Research Initiatives. “I’m working towards synergy across all of these programs so they’re not siloed,” she said. “The idea is to think about core elements of knowledge for our faculty for population health and health equity and engage stakeholders in our work.”

  • Melinda Irwin

    Associate Dean of Research and Professor of Epidemiology (Chronic Diseases); Associate Director (Population Sciences), Yale Cancer Center; Co-Program Leader, Cancer Prevention and Control, Yale Cancer Center; Deputy Director (Public Health), Yale Center for Clinical Investigation

    Deputy Director

    An athlete her entire life, Melinda Irwin, PhD, MPH, originally planned on specializing in orthopedics. But college courses in exercise physiology, nutrition and human anatomy led her to shift gears to public health. She ultimately decided to pursue a PhD, rather than an MD, in order to explore the connection between lifestyle factors and chronic disease.

    Since joining Yale in 2001, Dr. Irwin has concentrated on the role of lifestyle behaviors in cancer prevention and prognosis.

    This is increasingly relevant for breast cancer – the focus of much of her work - since mortality has decreased during the past two decades but survivors are at risk for recurrence and debilitating side effects due to treatment. Her work has shown that

    even after women have been diagnosed with breast cancer, they can substantially lower the risk of both recurrence and mortality by exercising. This holds true even for women who don’t become physically active until after their diagnosis.

    She has expanded her research into other cancers, showing that a moderate-intensity walking program improved physical functioning and reduced cancer-related fatigue in patients diagnosed with ovarian cancer. Dr. Irwin, who considers herself a biobehavioral researcher, is also examining the effect of exercise and weight loss on cancer biomarkers, showing that weight loss decreased C-reactive protein, a marker of systemic inflammation related to cancer. Her current research interests are focused on examining whether lifestyle behaviors also indirectly improve survival via improvements in medication adherence.

    “Given the improvement in treatment for many diseases, especially cancer, some people have a window of opportunity to change their lifestyle,” she said. “Others may already be living a healthy lifestyle but have difficulty maintaining it because of treatment, so we need to help them do that.”

    Dr. Irwin hopes that this line of research will lead to incorporating weight management and exercise management into the clinic as part of reimbursable cancer care, in much the same way that cardiac rehabilitation is now standard of care.

    Dr. Irwin is interested in the effects of exercise on other chronic diseases and is excited about her role at YCCI, which is allowing her to collaborate with faculty across the Yale campus. She is focusing on creating efficiencies between centers and expanding resources and opportunities for public health and population science research. She is equally eager to foster opportunities for junior faculty and feels better equipped to mentor younger colleagues after taking YCCI’s course on mentoring.

    “I hope to be able to give back in terms of more collaborations, synergies, efficiencies, and training opportunities,” she said.

  • Patrick O'Connor

    Dan Adams and Amanda Adams Professor of General Medicine; Chief, General Internal Medicine

    Chief of General Internal Medicine and Professor of Medicine at Yale, Dr. O'Connor's research has focused on the interface between primary care and substance abuse, resulting in nearly 200 scientific papers. His work has been published in leading medical journals including The New England Journal of Medicine, JAMA, The Annals of Internal Medicine, The Archives of Internal Medicine, The American Journal of Medicine, The Journal of General Internal Medicine, as well as in a number of substance abuse specialty journals.

    Dr. O’Connor has recruited and mentored a number of highly skilled clinical investigators (his faculty included 17 alumni of the RWJ Clinical Scholars Program) who are conducting groundbreaking work in clinical epidemiology, health services research, outcomes research and clinical effectiveness as well as focusing on chronic diseases such as diabetes, stroke, heart failure, cancer and substance abuse. Beginning with the recruitment and mentoring of Dr. D. Fiellin, and followed by the recruitment and mentoring of Drs. Justice, L Fiellin, and three new junior faculty—Drs. Tetrault, Becker and Edelman, Dr. O'Connor has built one of the most accomplished internal medicine-based substance abuse research programs in the United States.

    The research portfolio of this investigative group includes topics at the core of the Yale DAHRS program related to opioid dependence, alcohol use disorders, and the overlap between addiction and chronic pain. Dr. O’Connor’s accomplishments as a mentor and academic leader have been recognized by his receipt of two major national mentorship and leadership awards, one from the Association for Medical Education and Research on Substance Abuse (2005) and the other by The Society of General Internal Medicine (2007).

    During his tenure as Section Chief, Dr. O’Connor has successfully recruited a number of female faculty as well as faculty from underrepresented minority groups. He has built an internal medicine-based program focusing on research and education in substance abuse that includes several research staff and seven full-time faculty. Three of the senior faculty have held grants funded by the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism. Dr. O’Connor is the recipient of an R25 grant, Advancing Clinical Research Training Within Addiction Residency Programs, serving as MPI with Dr. Jeffery Samet.

    Dr. O’Connor has been the Principal Investigator on a number of research projects funded by the National Institutes of Health that explore topics at the core of the Yale-DAHRS program. Topics include:

    1. Integration of primary care and drug abuse treatment services
    2. Strategies for primary care-based opioid detoxification and opioid maintenance treatment
    3. Strategies for treating alcohol dependence in primary care settings
    4. Medical education about substance abuse

    Dr. O’Connor has been a highly active mentor and teacher in general internal medicine and specifically within the field of substance abuse. In recognition of his attributes as a mentor he received the Excellence in Mentorship award from the Association for Medical Education and Research in Substance Abuse (AMERSA) in 2005 and the Society of General Internal Medicine (SGIM)/Association of Chiefs & Leaders of General Internal Medicine (ACGIM) Chief’s Award in 2007.

    As Chief of General Internal Medicine (GIM) at Yale, he has transformed the program into the foremost GIM Section in the United States. He is the past President of AMERSA and is President-elect of the American Board of Addiction Medicine (ABAM).

  • Rajita Sinha

    Foundations Fund Professor of Psychiatry and Professor in the Child Study Center and of Neuroscience; Director, Yale Interdisciplinary Stress Center; Chief, Psychology Section in Psychiatry; Co-director of Education, Yale Center for Clinical Investigation

    Deputy Director for Interdisciplinary Research

    Rajita Sinha, PhD, has been fascinated by emotions since her youth, when she studied Indian classical dance, a disciplined practice filled with emotional expression. She later studied biological psychology and the physiological manifestations of emotion, working with addicts and people with psychiatric disorders. She was intrigued by brain mechanisms underlying stress, cravings and addiction. “The abundance of choices available in the world, and easy access to commodities, including highly palatable foods and drugs, challenges the body’s motivational systems in novel ways,” she said.

    Today, Dr. Sinha is internationally known for her pioneering research on the neural and biobehavioral mechanisms linking stress to addiction. She directs the Yale Stress Center, which was started with one of the largest interdisciplinary Consortium grants from the National Institutes of Health to study the effects of stress and self control effects on addictive behaviors and chronic disease. The collaborative research conducted at the Yale Stress Center by Dr. Sinha and other scientists includes the disciplines of neuroscience, genetics, psychiatry, basic neurobiology, diagnostic radiology, endocrinology, epidemiology and public health and clinical and behavioral outcomes. The Center is also developing and testing interventions to reverse the toxic effects of stress and loss of self control that drive addictive behaviors such as nicotine dependence, excessive alcohol use and overeating of comfort foods. Dr. Sinha is also examining the role of long-term stress and repeated stress exposures in alcohol and substance dependence to develop new therapies to reduce compulsive motivation for alcohol and drugs of abuse.

    Dr. Sinha’s work has shown that addiction itself debilitates the ability to handle stress, which has led her to conduct studies on medications to strengthen the brain circuitry involved in the ability to regulate emotions and cravings. Recognizing a reward/motivation component is obesity and food cravings, she is also conducting research in this area.

    Stress and addictions are major risk factors for cancer and chronic diseases, prompting Dr. Sinha to explore the biological underpinnings of these relationships. “We tend to divide up the body but that’s not how all diseases work,” she said. “What’s breaking the back of health care are the chronic diseases, which often occur in twos, threes, and fours. The challenge is in identifying the major risk factors and starting to address those, which allows us to think more broadly about these diseases.”

    In her interdisciplinary approach, Dr. Sinha utilizes neuroendocrine, physiological, neuroimaging, behavioral, neurocognitive, and clinical outcome approaches to explore stress and addiction interactions and their effect on chronic disease and health outcomes. She has also developed a clinical research core focused on developing large scale data sets to study genetic and environmental interactions that affect the risk of developing addictions and chronic disease. She brings her interdisciplinary focus to her mentees and her leadership role in YCCI, and the most important beneficiaries of this approach are the patients whose health is positively impacted by her work.

  • Kevan Herold

    C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)

    Deputy Director

    As a researcher who does both basic science and clinical research, Kevan Herold, MD, is ideally positioned to engage the basic science community in translational research that benefits patients.

    After spending 20 years doing research and teaching at the University of Chicago and Columbia University, Dr. Herold joined Yale in 2006 as the first recruit of the Human and Translational Immunology (HIT) program. He is widely recognized for his work on anti-CD3, a monoclonal antibody that quiets the T cells responsible for destroying insulin-producing beta cells in the pancreas. Starting in preclinical models and moving to investigations in humanized mice, Dr. Herold and his collaborators found that anti-CD3 induced T cells to migrate from the circulatory and lymph systems to the small intestine, where they produced the anti-inflammatory protein interleukin-10. When the cells returned to circulation, they had become regulators of the immune response that play a role in arresting the destruction of beta cells.

    He has translated this work to clinical trials in patients, where he has shown that anti-CD3 has a significant effect on preserving insulin production in patients with new onset Type 1 diabetes. He also developed a novel assay to measure beta cell death by determining the level of insulin DNA in the blood that contains epigenetic markers that identify it as being of beta cell origin. He most recently used this assay in subjects at risk for Type 1 diabetes that has challenged previous notions of disease mechanisms.

    Dr. Herold serves as director of the TrialNet Center at Yale, part of a consortium that conducts clinical trials to prevent Type 1 diabetes in those who are at high risk of developing the disease and treat newly diagnosed patients. Relatives of people with Type 1 diabetes have a 10 to 15 times greater risk for developing the disease than people with no family history. Family members are screened for diabetes-related antibodies; those who test positive can participate in studies designed to test medications – including an unprecedented multicenter trial with anti-CD3 - to prevent the disease from occurring. Dr Herold is also collaborating on studies to identify biomarkers in at-risk patients who progress to Type 1 diabetes.

    The treatments Dr. Herold is developing may have an impact on the lives of people who haven’t yet developed diabetes or aren’t aware they are at risk for developing it. “These are the people we’ll ultimately be able to help and that’s quite a strong motivation,” he said.

    In his role as YCCI’s deputy director, Dr. Herold has been instrumental in developing the Immune Monitoring Core and establishing a centralized biorepository for storing and tracking samples that is linked to Yale’s clinical research management system. “The depth it adds to the research is phenomenal,” he said.

  • Margaret Grey

    Annie Goodrich Professor of Nursing; Deputy Director, Yale Center for Clinical Investigation; Professor of Pediatrics (secondary)

    Deputy Director

    As a pediatric nurse practitioner, Margaret Grey, DrPH, RN, FAAN, is well aware of the toll that chronic illness takes on young patients. That’s why she has pursued research that aims to improve the lives of children with type 1 diabetes and prevent type 2 diabetes in high-risk children and adolescents.

    Dr. Grey’s research on coping skills training for teenagers with type 1 diabetes showed that it helps these young patients better control their blood sugar, which translates into reduced long-term complications. Leveraging teenagers’ interest in technology, she adapted this innovative program for the Internet and has also used it to study prevention of Type 2 diabetes in teens. She envisions a growing role for mobile technologies in helping patients manage and prevent other chronic diseases as well.

    Combined with her role in the development of practice-based research networks in nursing, Dr. Grey’s experience in community-engaged research make her ideally suited for her role as Deputy Director of YCCI and director of the Community Research Core. “All research ought to have a piece of community engagement,” she said, adding that community-engaged research may not necessarily happen in the community.

    It should, however, involve the community and address the concerns of its members. Dr. Grey and her team work closely with members of the New Haven community through the Cultural Ambassadors program, a group whose participation she considers to be integral to boosting community-engaged research and translation of findings within the community. She has also established ties with New Haven’s Mayor’s office and has created working groups with basic and clinical scientists, clinicians in the community, and community members to strategize research opportunities in areas that matter to New Haven’s residents.

    Her commitment to strengthening Yale’s community-engaged research activities is evident in her emphasis to train young investigators in this type of research. As director of the Community Research Core, she has provided opportunities for them to develop projects and obtain pilot funding. She believes that mentoring junior faculty members “assures the future of science,” and has mentored more than 100 trainees during her academic career.

    Dr. Grey notes that community-engaged research is interdisciplinary in nature and she has sought to leverage the expertise available at Yale by including leadership for the Community Research Core from across the medical campus. “I believe that by bringing together scientists from a multitude of disciplines with clinicians in our community health centers and community members, we can adapt innovative approaches,” she said. “Ultimately the collaborative work between the community and YCCI changes health in the area.”

  • Richard Bucala

    Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Micorbial Diseases); Deputy Chief, Section of Rheumatology

    Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health.  He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally.  Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders.  He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project.  Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

  • Sonia Caprio

    Professor of Pediatrics (Endocrinology)

    Pediatric endocrinologist Sonia Caprio, MD, recalls a time when obesity was so rare in children that they didn’t get type 2 diabetes, which was referred to as “adult onset diabetes.” Today, pediatric obesity has escalated to epidemic proportions and type 2 diabetes in children is on the rise.

    Dr. Caprio’s research focuses on the pathophysiology of juvenile obesity and type 2 diabetes, as well as its treatment. To combat obesity, she worked with registered dietician Mary Savoye, on a study to develop Bright Bodies, a weight management program for children that uses education, exercise and lifestyle modification. Today, hundreds of children are enrolled in Bright Bodies and it is “the pearl of our clinical work,” according to Dr. Caprio, professor of pediatrics (endocrinology).

    Yale was one of the first centers to point out the issue of pre-diabetes, which led to two major studies funded by the National Institute of Diabetes and Digestive and Kidney Diseases. The Treatment Options for Type 2 Diabetes in Youth (TODAY) examined different treatments for type 2 diabetes in adolescents and showed that these young patients have more rapidly progressive disease than those who are diagnosed as adults.

    The Restoring Insulin Secretion (RISE) study, for which Yale is one of only three participating centers in the country, also involves adolescents with pre- and early type 2 diabetes. RISE aims to prevent full blown diabetes in these patients by testing a new approach - insulin followed by metformin - compared to metformin alone. “The rational for using insulin for pre-diabetes is that by diminishing the level of glucose toxicity we may be able to prevent further beta cell loss,” said Dr. Caprio.

    She is conducting a study in the Hospital Research Unit with Robert Sherwin, MD, and Rajita Sinha, PhD, using functional MRI to study the effect of glucose and fructose on the brains of adolescents, who are the major consumers of soda in the U.S.

    She is also working with Savoye on a study to reduce fat content in the liver - a precursor to diabetes - by increasing the content of omega fatty acids in the diet. This study utilizes the CTSA-supported metabolic kitchen to prepare meals and the Church Street Research Unit (CSRU), YCCI’s outpatient research facility, to conduct oral glucose tolerance testing.For the past decade, she has been using the CSRU to test children for diabetes or pre-diabetes. In fact, it’s the first stop for every patient in every study she does.“Without that, we can’t determine the next study to do on the child,” she said. “The CTSA is my second home.”

  • Sarwat Chaudhry

    Associate Professor of Medicine (General Medicine); Co-Director, National Clinician Scholars Program; Vice-Chair/Chair-Elect, Dean’s Faculty Advisory Council

    Sarwat Chaudhry, MD is a board-certified internist who completed her clinical training at the University of Chicago. She came to Yale for the Robert Wood Johnson Clinical Scholars Program, and now holds a faculty position as Associate Professor of Medicine in the Section of General Medicine. Her work focuses on improving the care and outcomes of hospitalized patients, with a focus on older patients hospitalized for cardiovascular disease. Dr. Chaudhry serves as Director of the Academic Hospitalist Program at Yale. She recently founded the Center for Healthcare Innovation, Redesign, and Learning at Yale. This Center, funded by AHRQ, is studying and improving care transitions into, within, and out of the hospital setting. In March 2019 she was appointed Vice-Chair/Chair-Elect of the Dean’s Faculty Advisory Council.  

  • Paul D Cleary

    Anna M. R. Lauder Professor of Public Health (Health Policy) and Professor of Sociology and in the Institute for Social and Policy Studies; Director, Center for Interdisciplinary Research on AIDS (CIRA)

    Paul D. Cleary, Ph.D. is the Anna M.R. Lauder Professor of Public Health in the Department of Health Policy and Management. He served as Dean of the Yale School of Public Health from 2006 to 2017. He holds secondary positions as Professor of Sociology and in the Institute for Social and Institute for Social and Policy Studies. He directs the Yale Center for Interdisciplinary Research on AIDS (CIRA), which provides infrastructure support to over 50 research and training grants and over 180 affiliated scientists and community members.

    Dr. Cleary received his Ph.D. in sociology from the University of Wisconsin. His earliest work focused on studies of health behavior. He conducted theoretical and empirical research on smoking as well as patients’ perceptions and responses to physical symptoms and factors affecting use of medical care. He also studied the recognition and management of conditions such as mental illness, alcohol abuse and functional impairment in primary care settings.

    For more than 20 years, Dr. Cleary has been actively involved in research focused on persons infected with HIV. Since early in his career, he has investigated the ways in which infection affects people’s lives and the factors affecting the quality of medical care for infected persons. He led a key component of the HIV Costs and Services Utilization Study (HSCUS), in which his team investigated the physician and clinic characteristics that predict the quality of care that patients receive. He also conducted a major national evaluation of a quality improvement program in HIV clinics funded by the Ryan White Care Act.

    He has studied how organizational characteristics affect the costs and quality of care for persons with AIDS; evaluated a national continuous quality improvement initiative in clinics providing care to HIV infected individuals; and studied the long-term impact of patient-centered hospital care. He is Principal Investigator of one of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) projects funded by the Agency for Healthcare Research and Quality (AHRQ) to develop information gathering surveys for consumers regarding their health plans and services. He also is Principal Investigator and Director of the Yale Center for Interdisciplinary Research on AIDS (CIRA). He has published more than 300 journal articles describing his research.

    Dr. Cleary has been a member of the Academy of Medicine (AOM) since 1994 and served as Chair of two AOM Committees: the Committee on the Ryan White CARE Act: Data for Resource Allocation, Planning and Evaluation in 2002-2003, and the Committee on HIV Screening and Access to Care from 2010 to 2011. He has also been a member of the Connecticut Academy for Science and Engineering since 2007. In 1996, he was selected as a distinguished fellow of the Association for Health Services Research, and in 2002, received the Distinguished Investigator Award from the Academy for Health Services Research and Health Policy. In 2010, Dr. Cleary was awarded the Picker Award for Excellence in the Advancement of Patient-Centered Care by the Picker Institute.  In 2018, he received the L:eo G. Reeder Award for Distinguished Contributions to Medical Sociology.

    From 2005 to 2016 Dr. Cleary chaired the National Advisory Committee for The Robert Wood Johnson Foundation Investigator Awards in Health Policy Research Program. He has served as editor of The Milbank Quarterly, associate editor of the Journal of Health and Social Behavior, consulting editor of the Journal of Culture, Medicine and Psychiatry, and an editorial board member of The Handbook of Social Studies in Health and Medicine and the Advanced Handbook of Methods in Evidence Based Health Care.

  • Pietro De Camilli

    John Klingenstein Professor of Neuroscience and Professor of Cell Biology; Investigator, Howard Hughes Medical Institute; Chair, Department of Neuroscience; Director, Kavli Institute for Neuroscience and Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR)

    A native of Italy, De Camilli studied at the Liceo Manzoni in Milan, earned his M.D. degree from the University of Milano in 1972 and obtained a postgraduate degree in medical endocrinology from the University of Pavia in Italy. He was a postdoctoral fellow (1978-79) with Paul Greengard in the Department of Pharmacology at Yale, and subsequently an assistant professor in the Yale Section of Cell Biology. Following a return of a few years to Milan, he moved back to Yale in the late 1980s, where he is now John Klingenstein Professor of Neuroscience. He became an Investigator in the Howard Hughes Medical Institute in 1992. From 1997 to 2000 he served as Chair of the Department of Cell Biology and since 2005 he is Founding Director of the Yale Program in Cellular Neuroscience, Neurodegeneration and Repair. Since 2015, he serves as Chair of the Department of Neuroscience and Director of the Kavli Institute for Neuroscience.

    The De Camilli lab is interested in the cell biology of neuronal synapses. His studies on synaptic vesicle dynamics have contributed to the general fields of exocytosis and endocytosis. His research has provided insight into mechanisms of membrane fission and has revealed ways through which membrane-associated proteins can generate, sense and stabilize lipid bilayer curvature. His discovery and characterization of the role of phosphoinositide metabolism in the control of endocytosis have broad implications in the fields of phospholipid signaling and of membrane traffic. Building on this work, he has recently become interested in the role of membrane contact sites in the control of the homeostasis of bilayer lipids. His studies of synapses have also contributed to the elucidation of pathogenetic mechanisms of human diseases. 

  • Gail D'Onofrio

    Professor of Emergency Medicine; Chair, Department of Emergency Medicine

    “Academic faculty members need to be very proactive in their career trajectory,” said Gail D’Onofrio, MD, MS. “They need someone to help them navigate the academic waters. It’s an active process.”

    Dr. D’Onofrio has extensive experience mentoring dozens of young investigators from multiple disciplines at Yale and other institutions. She is Co-PI with Patrick O’Connor, MD, on a training grant from the National Institute on Drug Abuse (NIDA) to train Fellows from such fields as emergency medicine, internal medicine, obstetrics/gynecology, and pediatrics to become independent investigators focusing on drug use, addiction, and HIV prevention in general medical settings. She also leads grants from the Substance Abuse and Mental Health Services Administration (SAMSHA) to train primary care residents and students in the professions of medicine, nursing, social work, and counseling. Her mentees include researchers from fellow-CTSA sites like New York University and the University of North Carolina.

    As a mentor, Dr. D’Onofrio has a hands-on approach in helping junior colleagues align their interests with fundable research proposals; write grants; establish a professional network at Yale and in the wider community; and balance professional activities with scholarship.

    Dr. D’Onofrio is a national expert on heart disease in women and internationally known for her work in screening emergency department patients for alcohol and other drug use. A recent study published in the Journal of the American Medical Association was the first-known randomized trial comparing three treatment strategies for opioid-dependent patients receiving emergency care. Eighty percent of those treated with buprenorphine in the emergency department were engaged in treatment 30 days later and were less likely to use illicit opioids. Dr. D’Onofrio, co-PI David Fiellin, MD, and other colleagues are currently developing plans to expand this treatment model to multiple sites.

    Dr. D’Onofrio is committed to expanding the cadre of clinical researchers at Yale University. Working with Yale-New Haven Hospital—the fourth largest hospital in the United States—she said “we have the opportunity to enroll patients with a wide range of diseases and to work with community and outreach programs to improve the health of the public. Centralized CTSA-supported resources are critical to these efforts.”

  • James Duncan

    Ebenezer K. Hunt Professor of Radiology and Biomedical Imaging and Professor of Biomedical Engineering; Director of Undergraduate Studies in Biomedical Engineering; Vice Chair, Bioimaging Sciences in the Department of Diagnostic Radiology

    James Duncan, the Ebenezer K. Hunt Professor of Biomedical Engineering, has focused his research and teaching in the areas of biomedical image processing and analysis.

    Duncan, who holds joint appointments in diagnostic radiology and electrical engineering, is the associate chair and director of undergraduate studies in the Department of Biomedical Engineering as well as the vice-chair for bioimaging sciences research in diagnostic radiology. He is particularly interested in the use of model-based mathematical strategies for the analysis of biomedical images. He helped pioneer the use of geometrical models for segmenting deformable (typically anatomical) objects of approximately known shape and for tracking certain forms of non-rigid object motion, and later soft tissue deformation, most notably that of the heart.

    Duncan and his research team performed seminal work starting in 1987 on the use of parameterized global shape models to incorporate a notion of known prior object shape into the segmentation process using a Bayesian reasoning strategy, helping lead the way towards the use of strategies for automatically finding certain known anatomical structure from any of a variety of medical (e.g. computer tomography (CT), magnetic resonance imaging (MRI), ultrasound) and biological (e.g. confocal microscopy) images.

    The strategies he developed have resulted in major advances in bioimaging. He and his research collaborators have applied these strategies to locate the cortical gray matter layer and a variety of co-localized subcortical gray matter structures in the brain as well as to locate the structure near the prostate gland. More recently, Duncan’s team has begun to show that these same techniques will be useful for estimating gray matter-constrained activations from functional MRI data and could help guide the recovery of quantitative biochemical information from MR spectroscopy.

    Beginning in the late 1980s, Duncan also pioneered using shape features on the inner and outer surfaces of the heart wall as material tags for tracking left ventricular motion. This technique was successfully applied to other non-rigid tracking problems in cell biology and became the basis for a variety of efforts internationally. Duncan and his research team used this strategy for more sophisticated analysis in echocardiography. The team’s approach is now recognized in the medical-image-analysis community as among the first to incorporate true physical models into image analysis strategies and has helped develop a more general area of physical/biomechanical model-based re covery of both structural and functional information from biomedical images. Duncan’s laboratory has also developed initial forms of these techniques to estimate brain shift during epilepsy neurosurgery and guide fractionated prostate radiotherapy, among other uses. His work has resulted in three U.S. patents.

    Duncan is the principal investigator of major research funded by the National Institutes of Health. Before coming to Yale in 1983, he worked for Hughes Aircraft Company. He holds a B.S.E.E. from Lafayette College, an M.S. from the University of California at Los Angeles and a Ph.D. from the University of Southern California.

    Duncan is a fellow of the Institute of Electrical and Electronics Engineers (IEEE) and the American Institute for Medical and Biological Engineering. He is president of the International Society for Medical Image Computing and Computer Assisted Intervention and is a member of the American Association for Artificial Intelligence and the I.E.E.E. Computer Society, among other professional organizations.

  • Mark Gerstein

    Albert L Williams Professor of Biomedical Informatics and Professor of Molecular Biophysics & Biochemistry, and of Computer Science. Co-Director of the Yale Program in Computational Biology & Bioinformatics

    After graduating from Harvard with a A.B. in physics in 1989, Prof. Mark Gerstein earned a doctorate in theoretical chemistry and biophysics from Cambridge University in 1993. He did postdoctoral research in bioinformatics at Stanford University from 1993 to 1996. He came to Yale in 1997 as an assistant professor in the Department of Molecular Biophysics and Biochemistry, and since 1999, in the Computer Science Department. He was named an associate professor in 2001, and the following year became co-director of the Yale Computational Biology and Bioinformatics Program. Gerstein has published appreciably in the scientific literature, with >400 publications in total, including a number of them in prominent venues, such as Science, Nature, and Scientific American. His research is focused on bioinformatics, and he is particularly interested in data science & data mining, macromolecular geometry & simulation, human genome annotation & disease genomics, and genomic privacy. 

  • Thomas M. Gill

    Humana Foundation Professor of Medicine (Geriatrics) and Professor of Epidemiology (Chronic Diseases) and of Investigative Medicine; Director, Yale Program on Aging; Director, Claude D. Pepper Older Americans Independence Center; Director, Yale Center for Disability and Disabling Disorders; Director, Yale Training Program in Geriatric Clinical Epidemiology and Aging-Related Research

    As increasingly more people live active lives well into their seventies, eighties, and beyond, geriatric physicians are charged with helping their elderly patients live not only longer, but healthier lives. In his research and clinical practice, Thomas Gill, MD, Director of the Yale Program on Aging, addresses this challenge by drawing upon the wealth of knowledge from his clinical practice to inform his research.

    Dr. Gill’s research focuses on the mechanisms of the aging process and the impact of the inevitable decline in function - and the increase in disability - in older patients. His ongoing study, the Yale Precipitating Events Project, which began in 1998, has been closely monitoring a large cohort of elderly patients over more than 20 years, and has shed new light on the resiliency of older people to recover from debilitating events that can frequently occur during daily life. The study has changed how both family and professional caregivers view disability in the elderly, and how to manage it. An earlier clinical trial led by Dr. Gill showed that home-based physical therapy, or “prehabilitation,” is an effective strategy for preventing injury and stopping the effects of decline before they start. Dr. Gill is currently leading a large multi-site clinical trial that is evaluating the effectiveness of an evidence-based intervention to reduce the risk of serious fall injuries among vulnerable older persons.

    As a clinician, Dr. Gill, who began his career at Yale as a Robert Wood Johnson Clinical Scholar in 1991, sees the results of his research play out in the lives of the patients he treats, and finds new questions to ask as well. To him, research and clinical training go hand in hand. He encourages his clinically trained mentees to “take advantage of their clinical knowledge and experience when framing their research questions and hypotheses,” in order to distinguish themselves in their chosen fields.

  • Peter M. Glazer

    Robert E. Hunter Professor of Therapeutic Radiology and Professor of Genetics; Chair, Department of Therapeutic Radiology

    Radiation oncologist Peter M. Glazer, MD, PhD, is the chair of the Department of Therapeutic Radiology. He has dedicated his career to helping cancer patients receive the highest quality of care available in a supportive environment.

    “When patients are undergoing radiotherapy for cancer, it can be a sensitive and challenging time for them and their families,” he says. “Our team does everything possible to keep our patients safe and comfortable throughout treatment.” 

    Dr. Glazer makes it his priority to provide patients seeking care at Smilow Cancer Hospital and its Care Centers with the most advanced technologies and evidence-based treatments. “We take great pride in giving our physicians the best tools to treat cancer,” he says.

    As a professor of both therapeutic radiology and genetics at Yale School of Medicine, Dr. Glazer researches new therapeutic strategies for treating cancer and the role of altered DNA repair in tumor progression. His research was recently recognized by the National Cancer Institute of the NIH with a prestigious Outstanding Investigator Award of $7 million that will support his efforts to develop novel DNA repair inhibitors for cancer therapy.

  • Cary Gross

    Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Director, National Clinician Scholars Program at Yale

    “Remember what you are striving to accomplish as a researcher,” Cary Gross, MD, tells his mentees. “We are not simply trying to generate new knowledge, we are trying to generate knowledge that is relevant, and can eventually help people.” As a physician, researcher, and mentor, Dr. Gross is focused on easing the leap from the lab to real-world patient care.

    In his outcomes research, Dr. Gross examines the disconnect between evidence produced by clinical trials, and the experiences and needs of patients and populations. He has received NIH-funded grants to explore barriers to clinical trial enrollment, the impact of non-cancer illnesses on older persons with cancer, and the dissemination of new cancer screening and treatment methods into clinical practice. After documenting that older persons are disproportionately excluded from clinical research, Dr. Gross also demonstrated that applying trial results to patients who were above the age limit of trial eligibility was associated with a higher risk of harm.

    As a founding director of Yale’s Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Dr. Gross leads and conducts research on how to improve the care and outcomes of cancer patients. In a recent viewpoint published in JAMA, Dr. Gross and a colleague advocated for a new paradigm in cancer research, one that focuses on improving efficacy and value, as well as ensuring population health impact and generating new knowledge.

    Beyond his outcomes research, Dr. Gross serves as Director of the National Clinical Scholars Program, which is a key part of the YCCI training program and aims to create the next generation of change agents in the American healthcare system, by using an inter-professional training program that focuses on research skills, experiential training in leadership, and building a nuanced understanding of social determinants of health as well as health policy.

    Gross tells his mentees that their own research project may be only one step removed from directly influencing patient care, or it may be several steps, but the end goal is the same. Researchers who truly wish to effect change must “work with stakeholders who may have different perspectives than you, to understand the knowledge gaps that must be addressed to improve health and well-being.”

  • David A. Hafler

    William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology; Neurologist-in-Chief, Yale New Haven Hospital

    Dr. Hafler is the William S. and Lois Stiles Edgerly Professor and Chairman Department of Neurology, Yale School of Medicine and is the Neurologist-in-Chief of the Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York.

    Dr. Hafler received training in immunology at the Rockefeller University then at Harvard where he joined the faculty in 1984. He was one of the Executive Directors of the Program in Immunology at Harvard Medical School and was on the faculty of the Harvard-MIT Health Science and Technology program where he was actively involved in the training of graduate students and post-doctoral fellows.

    Hafler, in many respects, is credited with identifying the central mechanisms underlying the likely cause of MS. His early seminal work demonstrated that the disease began in the blood, not the brain, which eventually led to the development of Tysabri to treat the disease by blocking the movement of immune cells from the blood to the brain. He was the first to identify myelin-reactive T cells in the disease, published in Nature, showing that indeed, MS was an autoimmune disorder. He then went on to show why autoreactive T cells were dysregulated by the first identification of regulatory T cells in humans followed by demonstration of their dysfunctional state in MS. As a founding, Broad Institute member, Hafler identified the genes that cause MS, published in the New England Journal of Medicine and Nature. More recently, he identified the key transcription factors and signaling pathways associated with MS genes as potential treatment targets. Finally, he recently discovered that salt drives induction of these pathogenic myelin reactive T cells, both works published in Nature. Hafler was the Breakstone Professor of Neuroscience at Harvard, and became Chairman of Neurology at Yale in 2009, where he has built an outstanding clinical and research program that strongly integrates medical sciences. He has received numerous honors including the Dystel Prize from the AAN for his MS research and is among the most highly cited living neurologists.

  • Roy S. Herbst

    Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Director for Translational Research, Yale Cancer Center; Interim Director of Yale Center for Immuno-oncology, Yale Cancer Center

    Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.

    Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center (UT-MDACC) in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program.

    Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led.

    After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts.

    Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer.

    Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer.

    He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.

  • Amy Justice

    Professor of Medicine (General Medicine) and of Public Health (Health Policy); Clinical Research Director, Microbial Cancers

    With treatments constantly improving and patients living longer, HIV is now considered a chronic disease, and affects people in all walks of life, including many elderly. However, this wasn’t always the case. Amy Justice, MD, PhD, CNH Long Professor of Medicine and of Public Health began conceptualizing HIV as a chronic disease in 1997, when combination antiretroviral therapy began to take off. This was fully ten years before many in the field adopted the same way of thinking.

    As it was clear those with HIV would be living longer, Justice realized the importance of studying the impact of the disease on patients as they aged. That same year, Justice began the now renowned Veterans Aging Cohort Study (VACS). In the past  20+ years, VACS has followed more than 60,000 HIV-positive veterans who are matched to 120,000 HIV-negative veterans to determine how HIV, which, like many chronic diseases that take their toll on all systems of the body, affects medical and psychiatric health simultaneously. There are several smaller studies nested within the larger sample that include survey data, a tissue repository, and more in-depth evaluation of pulmonary and cardiac disease. Through the study, Justice has chronicled the shifting outcomes of chronic HIV infection, and seeks to use the disease as a model for better understanding chronic disease of all varieties.

    VACS received funded as a consortium by the National Institute of Alcohol Abuse and Alcoholism. The consortium will have a particular focus on how alcohol and substance abuse affects the health of people living with HIV for the long term.

    Dr. Justice draws upon her extensive experience analyzing large and complex observational dataset in her role as lead advisor to the Clinical Research Leadership Committee. This group is charged with shaping policy and resolving research issues identified in the context of health care delivery. Justice works with the committee to ensure that informatics services are research- and user-friendly.

    As a mentor, Dr. Justice finds that the mentor/mentee relationship is a mutually beneficial one. While she imparts guidance to them, her mentees she says, “see holes in arguments that may no longer be obvious when you’ve been working with something for a long time. It certainly keeps you on your toes.”

  • Naftali Kaminski

    Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary); Section Chief, Pulmonary, Critical Care & Sleep Medicine

    Dr. Naftali Kaminski is, as of July 1st, 2013, the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine. Before that he was a tenured professor of Medicine, Pathology, Computational Biology and Human Genetics, and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research at the University of Pittsburgh. Dr. Kaminski was the director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease and the Lung, Blood and Vascular Center for Genomic Medicine at the division of Pulmonary, Allergy and Critical Care Medicine in University of Pittsburgh. Dr Kaminski received his medical degree from the Hebrew University - Hadassah Medical School in Jerusalem, Israel, and completed a residency in Internal Medicine at Hadassah Mount-Scopus University Hospital in Jerusalem, and a fellowship in pulmonary medicine at Sheba Medical Center in Tel-Hashomer, Israel. Dr Kaminski received his basic science training in Dean Sheppard's laboratory at the Lung Biology Center at UCSF and in functional genomics and microarray technology at the Functional Genomics laboratory at Roche Bioscience, Palo-Alto. After his fellowship in 2000, Dr. Kaminski was appointed head of Functional Genomics at Sheba Medical Center in Israel, before being recruited to head the Simmons Center at the University of Pittsburgh in 2002.

    Dr. Kaminski's main research interests involve applying genomic approaches to elucidate basic mechanisms and improve diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic mostly lethal and currently untreatable scarring lung disease and other chronic lung diseases such Chronic Obstructive Pulmonary Disease (COPD), severe asthma and sarcoidosis. His group pioneered the application of high throughput genome scale transcript profiling in advanced lung disease. Among his key discoveries are: The discovery that matrix metalloproteases such as MMP7 and MMP19 have significant active roles in determining the lung phenotype in patients with IPF, demonstrating that microRNAs, a family of small non-coding RNAs, are differentially expressed in IPF, and that some of them such are mechanistically involved in lung fibrosis, and the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr. Kaminski's team identified a potential antifibrotic role for thyroid hormone signaling, a novel discovery with significant therapeutic implications. Dr. Kaminski has a strong interest in integrating high throughput ‘omics’ data, such as genome scale DNA variants, coding and non-coding RNAs, microbiome and metabolome information with clinical information to generate tools for personalized medicine of lung diseases that are significantly more precise, predictive and patient centered than anything that is currently available.

    Since completing his clinical training, Dr. Kaminski authored more than 260 research papers, review articles and book chapters and has given numerous invited talks at national and International conferences. Since he finished his fellowship in 2000, Dr. Kaminski has been consistently funded by NIH and is the PI of multiple NIH grants. Dr. Kaminski was a recipient of the Marvin I. Schwarz Award for contributions to patient care and research in pulmonary fibrosis from the Coalition for Pulmonary Fibrosis in 2010 and the University of Pittsburgh Innovator Award in 2012. In 2013, Dr. Kaminski received the American Thoracic Society Recognition of Scientific Achievements award, as well the Helmholtz Institute International Fellow. In 2015 he was elected to the Association of American Physicians. In 2016 he was elected as Fellow of the European Respiratory Society (ERS) , and won the the European Respiratory Society Gold medal for Interstitial Lung Disease. In 2018, Dr. Kaminski received the Andy Tager Excellence in Mentorship Award from the Respiratory Cell and Molecular Biology Assembly of the American Thoracic Society and was elected fellow  of the American Thoracic Society. Dr. Kaminski is active on the ATS and was the editor of “Gene Express”, a column on genomics in the initial days of the ATS Website, a member and chair of the Program Committee of the Assembly on Respiratory Cell and Molecular Biology of the ATS, and member of the ATS Research Advocacy Committee, and Chair of the Assembly on Respiratory, Cell, and Molecular Biology at the American Thoracic Society. He was an associate editor of the American Journal of Respiratory and Critical care Medicine, a member of multiple editorial boards and currently is the Deputy Editor of Thorax, BMJ. Dr. Kaminski is the current President of the Association of Pulmonary, Critical Care and Sleep Division Directors.

    Dr. Kaminski is passionate about training physician scientists for the challenges of 21st century medicine, and especially in the vocabulary, skills and technology of the new fields of genomics, bioinformatics, computational and system biology and their application to understanding the basic mechanisms that govern lung health and disease as well as to designed personalized medicine approaches and has mentored multiple MD and PhD scientists, of them many have productive and well funded independent career. He has most recently recognized for his commitment to mentoring with the American Thoracic Society Andy Tager excellence in mentoring award.

  • Mustafa Khokha

    Associate Professor of Pediatrics (Critical Care) and of Genetics

    We are interested in how embryonic pattern is generated and the resultant congenital malformations that occur when patterning fails. During development, the egg must activate a cascade of genes in order to form our body structure and establish correct pattern along the body axes. We are deeply interested in the gene regulatory networks that are necessary to create critical signals in specific embryonic locations at appropriate developmental stages. These signals must be carefully orchestrated in order to generate forms that are essential to function and the overall fitness of the organism.

    Our main approach is gene discovery from patients with congenital malformations, and then study them in our rapid, human model, Xenopus tropicalis. Recently, the remarkable advances in human genetics/genomics is transforming our understanding of the causes of congenital malformations. Traditionally gene discovery in these patients was very challenging, but new sequencing technologies enable gene discovery in these patients. In human studies, we have identified many new genes and are analyzing their patterning mechanisms in Xenopus. Combining human genetics with a high-throughput model system has allowed us to discover new genetic mechanisms and novel understanding of how development proceeds.

  • Harlan Krumholz

    Harold H. Hines, Jr. Professor of Medicine (Cardiology) and Professor in the Institute for Social and Policy Studies, of Investigative Medicine and of Public Health (Health Policy); Director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital; Co-Director, Robert Wood Johnson Foundation Clinical Scholars Program, Yale University

    “Our job is to help people who have great promise to achieve that promise,” said cardiologist Harlan Krumholz. Considered to be one of the leading experts in the world on quality-of-care research, Dr. Krumholz’s research over the last two decades has fundamentally elevated the quality of care for patients with cardiovascular disease. As director of the Yale Center for Outcomes Research and Evaluation (CORE), one of the nation’s first and most productive research units dedicated to improving patient outcomes and promoting better population health, he is eager to harness the wealth of data available via electronic health records. He is passionate about the ability of research to generate knowledge that produces insights that can help millions of people.

    Dr. Krumholz is equally passionate about mentoring the next generation of clinical investigators and has had a substantial impact on a large number of junior investigators. He is finishing 20 years as director or co-director of the Robert Wood Johnson Foundation (RWJF) Clinical Scholars Program, which has trained physician health leaders at Yale for more than four decades. He was the primary architect of the program’s enhanced training curriculum, which he saw as foundational to translating science into practice. When the RWJF program closes in 2016, he will serve as director emeritus of the Yale National Clinician Scholars Program, part of a national interprofessional fellowship program designed to prepare future clinician leaders to improve health and health care in the US through scholarship and action at the national, state, and local levels.

    Dr. Krumholz has served as primary mentor for for almost 100 individuals, many of whom have developed successful research careers. “Helping younger colleagues develop the skills they need to make the breakthroughs of the future is one of the most gratifying and essential aspects of my work,” he said.

    He feels that Yale has a small town culture that fosters an open, collaborative environment that is especially beneficial to early-stage investigators. He tells his mentees that while research presents challenges and frustrations, they should pursue areas about which they care deeply. “It has to be something that doesn’t feel like work,” he said, “but actually feels like a calling.”

    While Dr. Krumholz has much to offer his younger colleagues, he is often motivated and inspired by them. “The impact of my work would have only been a fraction of what it’s been if I hadn’t had the benefit of working with brilliant young people who have inspired me and are were tireless in their efforts to produce knowledge that’s going to help future generations,” he said.

  • John Krystal

    Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry and of Neuroscience; Chair, Department of Psychiatry; Chief of Psychiatry, Yale-New Haven Hospital; Director: NIAAA Center for the Translational Neuroscience of Alcoholism; Director, Clinical Neuroscience Division, VA National Center for PTSD

    Complex but common mental illnesses such as schizophrenia, alcoholism, and depression continue to challenge scientists, who seek ever better treatments for patients. John H. Krystal, MD, has made a career of delving to molecular levels of the brain to better understand how these psychiatric disorders function, and finding novel treatments for them in order to improve the lives of patients and their families.

    One of these novel treatments, for which Dr. Krystal is well known, made use of the street drug ketamine, infamously known as “Special K.” Dr. Krystal and a team of investigators successfully used the drug in the 1990’s to safely and transiently produce in healthy people symptoms and disturbances in brain function associated with schizophrenia and to probe the neurobiology of alcohol intoxication and alcoholism. His laboratory then discovered the rapid antidepressant properties of ketamine in humans. Ketamine is now administered widely for treatment-resistant symptoms of depression and one form of ketamine is now in Phase III clinical trials.

    Dr. Krystal has mentored several YCCI Scholars who study how the mechanisms of the brain at the molecular level impact behavior, relating to such disorders as cocaine addiction, mood disorder, delusions, and schizophrenia.

    “I learned very early on,” he said, of the days when he was a mentee himself, “to ask the important question, rather than the easy question, and then to design the most powerful experiment that could destroy it: what we used to call the ‘killer experiment.’ If the hypothesis could withstand these kinds of tests, then it might be more powerful.” Dr. Krystal feels that it is an important part of the scientific process to mentor young investigators, and pass on the lessons he has learned. “In some way, the way I can best have an impact on my field is by training people who will be future innovators.”

  • Ann Kurth

    Dean, School of Nursing, Linda Koch Lorimer Professor of Nursing and Professor of Epidemiology

    Ann Kurth, PhD, CNM, MPH, FAAN is Dean and Linda Koch Lorimer Professor, Yale University School of Nursing, and Professor of Epidemiology, Yale School of Public Health. Dr. Kurth is an elected Fellow of the National Academy of Medicine and a member of the 2014-2018 US Preventive Services Task Force, which sets screening and primary care prevention guidelines for the United States. Dr. Kurth is the 2018–2020 chair of the Consortium of Universities for Global Health. An epidemiologist and clinically-trained nurse-midwife, Dr. Kurth’s research focuses on HIV/reproductive health and global health system strengthening. Her work has been funded by the National Institutes of Health (NIAID, NIDA, NIMH, NICHD), the Bill & Melinda Gates Foundation, UNAIDS, CDC, HRSA, and others, for studies conducted in the United States and internationally.

    Dr. Kurth has published over 200 peer-reviewed articles, book chapters, and scholarly monographs and presented at hundreds of scientific conferences and invited talks. She has received awards for her science and leadership including the Friends of the National Institute of Nursing Research Ada Sue Hinshaw Research Award and the International Nurse Researcher Hall of Fame award from Sigma Theta Tau International. Dr. Kurth is a member of the National Academy of Medicine, the Connecticut Academy of Science and Engineering.

  • Professor of Medicine (Cardiology); Director, Cardiology; Director of Yale UCLP Clinical Research Program Yale University School of Medicine, New Haven, CT, The Barts Heart Center and Queen Mary University of London, Cardiology

    Alexandra J. Lansky, MD, is Professor of Medicine in the section of Cardiology at the Yale School of Medicine and a practicing cardiologist at Yale-New Haven Hospital, in New Haven, CT. Dr. Lansky joined Yale in 2010 as Director of the Yale Heart and Vascular Clinical Research Program and the Cardiovascular Research Center (YCRC), which specializes in the conduct of national and international cardiovascular clinical trials with specific expertise in the evaluation of interventional devices. She most recently received a dual appointment as Chair of Cardiovascular Research at Queen Mary University in London as part of the Yale and London based Barts Heart Center transatlantic research collaboration. From 2004 to 2010 Dr. Lansky was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Clinical Services at the Center for Interventional Vascular Therapy, a practicing cardiologist at New York-Presbyterian, and Chief Scientific Officer of the Cardiovascular Research Foundation Clinical Trials Center.Prior to that she was an interventional cardiologist on faculty at Washington Hospital Center in Washington, DC, and at Lenox Hill Hospital in New York, NY.

    She has dedicated her career to leading clinical and angiographic evaluations of more than 500 clinical trials in a broad range of ischemic cardiovascular therapeutic areas, including pharmacologic and interventional device trials, many of which are landmark trials in the field and/or leading to FDA approval in the United States. She has served as the principal investigator on numerous national and international imaging studies, device, DES and neuroprotection trials. Dr. Lansky has authored and coauthored over 500 academic peer-reviewed manuscripts in the fields of interventional cardiology, angiography, and women’s cardiovascular health. She chaired the American Heart Association Statement on Interventions in Women and most recently the Academic Research Consortium defining Neurologic Endpoints in clinical cardiovascular trials.

    Dr. Lansky has been recognized for her outstanding clinical research contributions with several prestigious awards including: Masters of Arts Privatim from Yale University in 2017; Thompson Reuter’s 2014 and 2016 “Most influential Scientific Minds for Clinical Medicine”; 2012 Wenger Award of Clinical Excellence in Women’s health, Visiting Professor at Fu Wai Hospital, Bejing, China and Honorary Professor, University College London.

    Dr. Lansky is board certified in cardiovascular diseases. A graduate of the Medical College of Virginia in Richmond, VA, she received her residency training in internal medicine, cardiology, and interventional cardiology at Washington Hospital Center, Washington DC. Dr. Lansky is a Fellow of the European Society of Cardiology,the American College of Cardiology, the American Heart Association and the Society of Cardiac Angiography and Interventions.

  • Richard Lifton

    Professor (Adjunct) of Genetics

    Richard Lifton is Professor, Adjunct of Genetics. Lifton was the Chair of the Department of Genetics from 1998-2016, Sterling Professor of Genetics and Internal Medicine, Founder and Executive Director of the Yale Center for Genome Analysis and Investigator of the Howard Hughes Medical Institute at Yale School of Medicine.He graduated summa cum laude from Dartmouth College, then received MD and PhD degrees (in Biochemistry) from Stanford University. Following clinical training in Internal Medicine at Brigham and Women’s Hospital, he continued on the faculty at Harvard Medical School before being recruited to Yale in 1993.

    Lifton has used human genetics and genomics to identify rare mutations with large effect and elucidate biochemical mechanisms underlying diverse common diseases.In the particular case of hypertension, which affects more than a billion people worldwide and is a principal risk factor for heart attack, stroke and heart failure, together the leading cause of death worldwide, Lifton’s work has identified mutations and biochemical mechanisms that drive blood pressure to the highest and lowest blood pressures compatible with survival, implicating altered renal salt reabsorption in blood pressure variation. This work has also identified a previously unrecognized pathway that orchestrates the balance between salt and potassium homeostasis, providing a mechanism for dietary potassium’s ability to lower blood pressure. These findings provided the scientific basis for reducing salt balance in the prevention and treatment of hypertension, strategies that are used worldwide. Finding mutations underlying extreme outliers of common disease to identify pathways that can manipulated for health benefit has been broadly applied.

    In 2009 Lifton’s group developed exome sequencing, selectively sequencing all of the genes in the human genome at very low cost, and demonstrated the utility of the technology by performing the first clinical diagnosis by genome-level sequencing. This technology has been widely used for discovery of hundreds of disease and trait loci. Lifton’s group has used this technology to discover genes underlying diverse cardiovascular, renal, and neoplastic diseases. These include discovery of mutations in chromatin modifiers that underlie congenital heart disease, and discovery that hormone-producing tumors are commonly caused by single somatic mutations.

    Lifton is an elected member of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences.He has served on the Governing Councils of the National Academy of Sciences, the National Academy of Medicine, the Advisory Council to the NIH Director, the Scientific Advisory Boards of the Whitehead Institute of MIT, the Broad Institute of MIT and Harvard, the Simons Foundation for Autism Research and the Massachusetts General Hospital. He has also served as Co-Chair of the Planning Committee for the President’s Precision Medicine Initiative.

    Lifton has received the highest scientific awards of the American Heart Association, the American Society of Nephrology, the Council for High Blood Pressure Research, the American Society of Hypertension, the International Society of Hypertension, and the International Society of Nephrology.He received the 2008 Wiley Prize for Biomedical Sciences and the 2014 Breakthrough Prize in Life Sciences.

  • Linda Mayes

    Arnold Gesell Professor of Child Psychiatry, Pediatrics and Psychology in the Yale Child Study Center; Chair, Yale Child Study Center; Special Advisor, Dean

    Dr. Linda Mayes is the Arnold Gesell Professor of Child Psychiatry, Pediatrics, and Psychology and Director of the Yale Child Study Center. She is also Special Advisor to the Dean in the Yale School of Medicine. Trained as a pediatrician, Dr. Mayes’s research focuses on stress-response and regulatory mechanisms in young children at both biological and psychosocial risk. She has especially focused on the impact of prenatal substance use on children’s long-term outcomes. She has made contributions to understanding the mechanisms of effect of prenatal stimulant exposure on the ontogeny of arousal regulatory systems and the relation between dysfunctional emotional regulation and impaired prefrontal cortical function in young children. She has published widely in the developmental psychology, pediatrics, and child psychiatry literature.

    Given the nature of her work with children at significantly high-risk for developmental impairments from both biological and psychosocial etiologies, Dr. Mayes also focuses on the impact of parenting on the development of arousal and attention regulatory mechanisms in their children, and specifically on how substance abuse impacts reward and stress regulatory systems in new parents. With other colleagues in the Center, she studies how adults transition to parenthood, especially when substance abuse is involved, and the basic neural circuitry of early parent-infant attachment using both neuroimaging and electroencephalographic techniques. She and her colleagues have developed a series of interventions for parents including an intensive home-based program called Minding the Baby.

    Dr. Mayes's research programs are multidisciplinary, not only in their blending basic science with clinical interventions but also in the disciplines required including adult and child psychiatry, behavioral neuroscience, obstetrics, pediatrics, and neuropsychology.

    She is also a Distinguished Visiting Professor in psychology at Sewanee: The University of the South where she is working on intervention programs to enhance child and family resilience.

  • Ruth McCorkle

    Florence Wald Professor Emeritus of Nursing; Interim Specialty Director, Adult Health

    A pioneer in oncology nursing, Ruth McCorkle has been named the first Florence Schorske Wald Professor at the Yale School of Nursing (YSN). McCorkle is currently professor of Nursing, former director of the Center for Excellence in Chronic Illness Care, and she was chair of the Doctor of Nursing Science Program from 1998-2004. She was also the program leader for Cancer Control at the Yale Comprehensive Cancer Center (YCCC) from 1998-2000 and a professor in the Department of Epidemiology and Public Health at the Yale School of Medicine. She is currently Director of Psychosocial Oncology at YCCC.

    McCorkle received a bachelor's degree in nursing from the University of Maryland and a master's in medical-surgical nursing from the University of Iowa. Her doctorate, in mass communications, was earned at the University of Iowa's School of Journalism. She has held teaching positions at a variety of institutions across the country, including the University of Pennsylvania, the University of Washington, and the University of Iowa.

    McCorkle's interest in cancer and palliative care is longstanding. Over 40 years ago she studied at St. Christopher's Hospice in London, England, and participated in clinical studies to relieve distressing symptoms associated with dying. Since then, she has been continuously funded by the National Institutes of Health and other prestigious groups for her studies on managing life with cancer.

    Elected to the Institute of Medicine in 1990, McCorkle is the recipient of numerous scholarships and awards. Some of her many honors include the Book of the Year Award for Cancer Nursing from the American Journal of Nursing, a Distinguished Merit Award from the International Society of Nurses in Cancer Care, and a Distinguished Research Award from the Oncology Nursing Society. She was named the Nurse Scientist of the Year by the Council of Nurse Researchers of the American Nurses Association, one of the most coveted awards in the field of nursing. In 2009, she received the Bernard Fox Research Award for outstanding contribution to the field of Psycho-Oncology. In 2011, she received the Jimmie Holland Leadership award and the Trish Green Quality of Life Award. She received a Lifetime achievement Award from the Oncology Nursing Society in 2013 and Yale Cancer Center in 2017. The American Academy of Nursing named her a Living Legend in 2018. A prolific writer, her work appears in many professional journals in the US and abroad.

  • Ruslan Medzhitov

    Sterling Professor of Immunobiology; Investigator, Howard Hughes Medical Institute

    Medzhitov was born in Tashkent, Uzbekistan, and earned a B.S. at Tashkent State University before going on to pursue a Ph.D. in biochemistry at Moscow University in 1990. He performed his postdoctoral studies with the late Charles A. Janeway Jr. at Yale University Medical School.

  • Perry Miller

    Professor Emeritus of Anesthesiology

    Prof. Miller is the founder and previous Director of the Yale Center for Medical Informatics (YCMI) and of Yale’s Biomedical Informatics research training program. Biomedical Informatics is a discipline at the intersection of biomedicine and the computing and information sciences. The field focuses on the creative application of computers in clinical medicine, biomedical research, and medical education. In clinical medicine, the growing use of computers in patient care, education, and research makes the field increasingly important. In biomedical research, informatics is rapidly becoming a critical component of virtually all bioscience fields. Prof. Miller's research includes major initiatives in clinical, neuro-, and genome informatics, as well as interdisciplinary research at the intersections of these fields.

  • Laura Niklason

    Nicholas Greene Professor of Anesthesiology and Professor of Biomedical Engineering; Division Chief; Vice Chair, Research

    Dr. Niklason is the Nicholas M. Greene Professor at Yale University in Anesthesia and Biomedical Engineering, where she has been on faculty since 2006. Dr. Niklason’s research focuses primarily on regenerative strategies for cardiovascular and lung tissues. Niklason’s engineered blood vessels are currently in clinical trials, and are the first life-sustaining engineered tissue to be studied in any Phase III trial. Niklason’s lab was also one of the first to describe the engineering of whole lung tissue that could exchange gas in vivo, and this work was cited in 2010 as one of the top 50 most important inventions of the year by Time Magazine. She was inducted into the National Academy of Inventors in 2014, and was elected to the National Academy of Medicine in 2015.

    Niklason received her PhD in Biophysics from the University of Chicago, and her MD from the University of Michigan. She completed her residency training in anesthesia and intensive care unit medicine at the Massachusetts General Hospital in Boston, and completed post-doctoral scientific training at Massachusetts Institute of Technology.

  • Mary O'Connor

    Professor of Orthopaedics and Rehabilitation; Director, Center for Musculoskeletal Care

    As the inaugural Director of the Center for Musculoskeletal Care at Yale School of Medicine and Yale-New Haven Health, Dr. O'Connor brings together the traditional disciplines of orthopaedics, rheumatology, spine and sports medicine with ancillary services such as nutrition, behavioral health and complementary medicine to create a Center focused on integration, innovation and invigoration of patients, providers and payers. Research is a critical activity and includes translational studies and those targeting biological therapies for musculoskeletal conditions.

    After graduating from Yale University with a degree in biochemistry, Dr. O'Connor attended Drexel University College of Medicine and the completed her orthopaedic surgery residency and fellowship at Mayo Clinic, Rochester, MN. She joined the staff at Mayo Clinic in Florida (MCF) and held numerous leadership roles including Chair of the Department of Orthopedic Surgery (MCF), Medical Director for Philanthropy (MCF), member of the Executive Operations Team (MCF) and Medical Director of the Office of Integrity and Compliance for Mayo Clinic. She has also served as President of the International Society of Limb Salvage, the American Association of Hip and Knee Surgeons, the Musculoskeletal Tumor Society, the Association of Bone and Joint Surgeons and the Ruth Jackson Orthopaedic Society. She is the Chair of the American Academy of Orthopaedic Surgery Diversity Advisory Board and Chair of the Movement is Life Caucus, a multi-stakeholder group committed to decreasing musculoskeletal healthcare disparities.

  • Executive Vice President, Chief Medical Officer (Aetna)

    Harold Paz, MD, MS is executive vice president and chief medical officer of Aetna. Before joining Aetna, Dr. Paz served as chief executive officer of Penn State Hershey Medical Center and Health System, senior vice president for Health Affairs for Penn State University, dean of its College of Medicine and professor of medicine and public health sciences for eight years. Prior to his appointment to Penn State, he served as dean of the Robert Wood Johnson Medical School and chief executive officer of Robert Wood Johnson University Medical Group, the largest multispecialty group practice in New Jersey, and professor of medicine. During his tenure at Penn State, Dr. Paz initiated the formation of the Penn State Hershey Health System, which includes four hospitals, 64 ambulatory care practices, and 18 affiliated hospitals.

    Dr. Paz received a master of science in life science engineering from Tufts University and his medical degree from the University of Rochester School of Medicine and Dentistry. He completed his internship and residency at Northwestern University, where he served as chief medical resident and instructor in clinical medicine. He was a Eudowood Fellow in pulmonary and critical care medicine at Johns Hopkins Medical School. In addition, he was a post-doctoral fellow in environmental health science at Johns Hopkins School of Hygiene and Public Health.

    Dr. Paz has focused his medical practice on pulmonary medicine with a special interest in patients with sarcoidosis. His research looks at critical care clinical outcomes, health system organization, and health care effectiveness. A pioneer in the field of quality management, he was among the first to study clinical outcomes in the intensive care unit. From this early work, he recognized the need to formally train physicians in quality, and in 1993 he started the first fellowship of its kind in quality management.

  • Lois S. Sadler

    Professor of Nursing and in the Child Study Center; Professor, School of Nursing and Yale Child Study Center

    Lois S. Sadler is a Professor at the Yale School of Nursing and the Yale Child Study Center, where she teaches master’s and doctoral nursing students in the areas of family studies, child and adult development, pediatric health promotion, research, research ethics and adolescent health. Dr. Sadler received her BS degree from the University of Massachusetts, her MSN degree from Yale University School of Nursing, and her PhD from the School of Family Studies at the University of Connecticut. She has worked as a Pediatric Nurse Practitioner with teen parents in New Haven since 1979.

    Dr. Sadler’s research is in the area of the transition to parenthood among urban adolescent parents and their families, adolescent pregnancy prevention, and evaluation of specialized support programs for at-risk young parents and their children. Her publications and presentations are in the area of adolescent primary health care issues, community-engaged research, high risk families, adolescent parenthood, and home visiting. In 2014, the home visiting program, Minding the Baby®, developed and tested with colleagues from the Yale Child Study Center was designated by the Department of Health and Human Services as an evidence-based home visiting model, one of only 19 models nationwide. The MTB program is being implemented in Connecticut, Florida, Denmark, England and Scotland. A home visiting program adapted from MTB is being implemented and tested in Sao Paulo, Brazil. 

    Dr. Sadler’s current research includes serving as mPI with Dr. Nancy S. Redeker on an NINR-funded community-based mixed methods study of sleep patterns and healthy sleep intervention development with multicultural community families raising young infants and children.

  • W. Mark Saltzman

    Goizueta Foundation Professor of Biomedical Engineering and Professor of Cellular and Molecular Physiology and of Chemical Engineering, Head of Jonathan Edwards College; Department Chair, Biomedical Engineering

  • Gerald Shulman

    George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology; Investigator, Internal Medicine; Co-Director, Yale Diabetes Research Center, Internal Medicine; Director, Yale Mouse Metabolic Phenotyping Center, Internal Medicine

    Gerald Shulman, MD, PhD, has long been fascinated by diabetes and metabolism. As a young boy attending a summer camp for children with diabetes where his father was the camp physician, he was struck by his fellow campers lining up for their insulin shots. In college, while studying biochemistry and physiology, he got hooked on the intricacies of metabolism. He came to Yale in 1983 as a postdoctoral fellow in order to use NMR spectroscopy to study biochemistry in humans in real time.

    Today, he is known for pioneering the use of in vivo NMR spectroscopy to study glucose and lipid metabolism in both humans and rodents. Leading an interdisciplinary team of chemists, NMR spectroscopists, cell biologists, clinical physiologists, electrical engineers, organic chemists, nutritionists and nurses, he is focused on understanding the mechanisms of insulin resistance. His research has led to the identification of fatty metabolites that build up in liver and muscle cells and trigger the insulin resistance that leads to type 2 diabetes. “It’s not so much how much fat we have that leads to insulin resistance and diabetes, it’s the intracellular accumulation that causes problems,” he said.

    His research, which utilizes such CTSA-supported resources as the Hospital Research Unit and the Magnetic Resonance Research Center, has led to major advancements in our understanding of the mechanisms underlying diabetes. His team found that treatment with leptin, a hormone that controls feelings of fullness, reverses hyperglycemia in rats with poorly controlled type 1 and type 2 diabetes. While previous studies had shown that leptin lowered plasma glucagon, a hormone that raises blood sugar levels, Shulman’s group found that leptin actually inhibits the hypothalamic-pituitary-adrenal axis, a major neuroendocrine pathway that controls the body’s reaction to stress and regulates digestion, energy storage, and metabolism.

    Dr. Shulman and his colleagues identified the molecular mechanism by which insulin inhibits glucose production by the liver and why this process stops working in patients with type 2 diabetes. They showed that acetyl CoA is a key molecule in regulating the conversion of amino acids and lactate to glucose and that reversal of this process, due to inflammation in fatty tissue, leads to increased hepatic glucose production in rats and humans. “None of the drugs we currently use to treat type 2 diabetes target the root cause,” he said. “By understanding the molecular basis for hepatic insulin resistance we now can design better and more effective drugs for its treatment.”

    Studying the effects of mitochondrial protonophore 2,4-dinitrophenol (DNP), a weight loss agent that is known to be toxic, Dr. Shulman found that its toxicity was related to its peak plasma concentrations. He showed that reformulating it can safely reverse nonalcoholic fatty liver disease (NAFLD) and reduce blood glucose, triglyceride and insulin concentrations in rodents with NAFLD and type 2 diabetes. He went on to develop a new oral, controlled-release form of DNP known as CRMP, which is equally effective with no adverse effects. The next step will be to translate these findings so that this approach can be used to safely and effectively treat patients with diabetes.

  • Stefan Somlo

    C. N. H. Long Professor of Medicine (Nephrology) and Professor of Genetics; Chief, Section of Nephrology

  • Hugh Taylor

    Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology; Chair of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine; Chief of Obstetrics and Gynecology, Yale-New Haven Hospital

    Many Yale faculty members have been honored for their research impact, but some, like Hugh Taylor, MD, have been recognized as mentors as well. Named as the American College of Obstetricians and Gynecologist’s Mentor of the Year in 2013, Dr. Taylor sees the mentoring process as a “win-win” for both mentors and mentees. “I find that bringing in young, bright minds will inform my research,” he says, “and hopefully I can impart my experience to them. Together as a team, we are better than either of us alone.”

    Dr. Taylor’s clinical research centers on implantation, endometriosis and menopause. His basic science research focuses on uterine development, the regulation of developmental gene expression by sex steroids, endocrine disruption, and stem cells. He is a recipient of eight National Institutes of Health research grants, and directs the Yale Center for Reproductive Biology.

    Dr. Taylor, who has published more than 200 articles in his field, has also been awarded the International Fundacion IVI Award< for best clinical research record in reproduction medicine, chosen from a pool of prestigious candidates for the impact his body of research has made on the field of reproduction medicine.

    While Dr. Taylor says he always knew in his heart that he was headed toward a career focused on research and investigation, it was his mentors when he was in training at Yale who helped guide him toward his particular field. Those mentors, he says, “made that area exciting and accessible, and showed me the potential value for that research, and how it could make a big difference.”

    Making a difference is an important piece of the advice Dr. Taylor gives his own mentees. He advises junior scholars to “look for areas that are underserved, where they could use a fresh new approach. That's where you are really needed, and where you will have success.”

  • Mary Tinetti

    Gladys Phillips Crofoot Professor of Medicine (Geriatrics) and Professor in the Institution for Social and Policy Studies; Section Chief, Geriatrics

    Dr. Tinetti is a Professor of Medicine and Public Health and is Chief of Geriatrics at Yale School of Medicine. She is a leading expert in the area of falls and fall injury risk factors identification and prevention. Her current research focus is on clinical decision-making for older adults in the face of multiple health conditions, measuring the net benefit and harms of commonly used medications, and the importance of cross-disease universal health outcomes. She is leading a national effort to develop and test an approach to health care that realigns primary and specialty care to focus on the health priorities of older adults with multiple conditions. She also chairs a group of advisors helping large health systems be Age-Friendly. Dr. Tinetti’s work is funded by the NIH and several foundations. She has published over 200 original peer reviewed articles.  She has served on several national advisory committees including the FDA, NCQA, NQF. Dr. Tinetti has received numerous awards and is a member of the National Academy of Medicine and is the recipient of a MacArthur Foundation fellowship.

  • Director, US Medical Affairs and Clinical Development (Respiratory), Boehringer Ingelheim Pharmaceuticals, Inc.

    As Director of Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals Inc., Dr. Wang recognizes the importance of having the opportunity to train the next generation of clinical researchers and to expose them to opportunities outside of academia. Her current position at BIPI and former positions as Senior Director of Clinical Research at Replidyne Inc and Vice President of Clinical Development at Sanofi Pasteur afford her the ability to offer trainees the industry perspective of clinical research and insights into the drug development process.

    At the same time, Dr. Wang is well acquainted with conducting research at an academic institution. Earlier in her career, I had a primary appointment as Associate Professor in Pediatrics and cross appointment at the Institute of Health Policy, Management and Evaluation (IHPME) at the Hospital for Sick Children and the University of Toronto. Her academic research examined diagnostic evaluation, prognostic markers, and interventions in respiratory infections, particularly those due to respiratory syncytial virus (RSV).

  • Kimberly Yonkers

    Professor of Psychiatry, of Epidemiology (Chronic Diseases) and of Obstetrics, Gynecology, and Reproductive Sciences; Director, Division of Psychological Medicine; Director, Center for Wellbeing of Women and Mothers

    I have a strong history in the conduct of clinical trials and cohort studies.  My clinical research spans several decades and has been predominantly funded by federal research grants.  A list of some of these projects are listed below and include datasets amenable to secondary analyses:

    1) The Yale Pink and Blue study, a large cohort study of ~2700 women who were followed for psychiatric and obstetric complications and outcomes through pregnancy and into the postpartum period.

    2) The Symptom Onset Study randomized 193 women with premenstrual dysphoric disorder to treatment with sertraline or similarly appearing placebo that was initiated at the onset of premenstrual symptoms.  Monthly and daily ratings were collected for at least 2 evaluation cycles and 6 cycles of double blind treatment.

    3) Project START (Screeening to Augment Referral to Treatment) randomized 176 pregnant women with hazardous substance use to psychological treatment provided on-site or usual care, and followed them for 2 years.

    4) The Progesterone treatment for Cocaine (ProCo) study randomized 40 women with pre-conceptional cocaine use disorder to postpartum treatment with oral micronized progesterone or placebo

    5) Comparison of Screening measures for detection of substance misuse in pregnant women.  This is a 3-center cross-sectional study of 1200 gravidas.  The goal was to compare 5 screening instruments on measures of merit.

    6) Project MISA is a study of ways to integrate use of motivational interviewing into a general medical setting.

  • Hongyu Zhao

    Department Chair and Ira V. Hiscock Professor of Biostatistics, Professor of Genetics and Professor of Statistics and Data Science

    Dr. Hongyu Zhao is the Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Data Science and Genetics, Chair of the Biostatistics Department and the Co-Director of Graduate Studies of the Inter-Departmental Program in Computational Biology and Bioinformatics at Yale University. He received his B.S. in Probability and Statistics from Peking University in 1990 and Ph.D. in Statistics from the University of California at Berkeley in 1995. His research interests are the applications of statistical methods in molecular biology, genetics, drug developments, and precision medicine.

    Some of his recent projects include large scale genome wide studies to identify genetic variants underlying complex diseases, genetic risk prediction, biological network modeling and analysis, disease biomarker identification, genome annotation, cancer genomics, microbiome analysis, single cell analysis, image analysis, and systems biology study of herbal medicine. He has published over 480 articles in statistics, human genetics, bioinformatics, and proteomics, and edited two books on human genetics analysis and statistical genomics. He has trained over 70 doctoral and post-doctoral students, many of whom are holding tenured or tenure-track positions at major universities in the states and overseas.

    Dr. Zhao is a Co-Editor of the Journal of the American Statistical Association Theory and Methods, and serves on the editorial boards of several leading statistical and genetics journals. He was the recipient of the Mortimer Spiegelman Award for a top statistician in health statistics under the age of 40 awarded by the American Public Health Association and the Pao-Lu Hsu Award from the International Chinese Statistical Association. His research has also been recognized by the Evelyn Fix Memorial Medal and Citation by UC Berkeley, a Basil O'Connor Starter Scholar Award by the March of Dimes Foundation, election to the fellowship of the American Association for the Advancement of Science, the American Statistical Association, and the Institute of Mathematical Statistics.